A Phase I Study to Evaluate the Safety, Tolerability, Pharmacokinetic Characteristics and Preliminary Efficacy of BL-M17D1 in Patients With Locally Advanced or Metastatic HER2 Positive/Negative Breast Cancer and Other Solid Tumors
Latest Information Update: 14 Nov 2024
At a glance
- Drugs BL M17D1 (Primary)
- Indications Advanced breast cancer; HER2 negative breast cancer; HER2 positive breast cancer; Solid tumours
- Focus Adverse reactions
- Sponsors Sichuan Baili Pharmaceutical
- 19 Sep 2024 Status changed from not yet recruiting to recruiting.
- 23 Jul 2024 New trial record